TAIPEI, November 3, 2022 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, today announced that the Phase 2b clinical data from 49 patients receiving RGI-2001 for the prevention of acute graft-versus-host disease (aGVHD) will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting […]ClinDatrix has provided the clinical services necessary for this challenging clinical trial.
The Experience of Big. The Advantage of Value.
- About Us
- Services
- Clinical Trial Project Management
- Clinical Trial Investigator Meetings & Event Planning
- Clinical Trial Monitoring
- Clinical Trial Medical Monitor & Medical Safety
- Clinical Trial Data Management
- Clinical Trial Biostatistics
- Medical Writing Services
- Clinical Regulatory Affairs
- Quality Assurance for Clinical Trials
- Clinical Trials Consultant
- Therapeutic Areas
- Medical Devices
- Technology
- Global Affiliates
- Careers
- Contact Us
Home » News & Events » REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 ASH Annual Meeting